Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Osavampator

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurocrine Reports Positive Ph 2 Osavampator Data In MDD
    Neurocrine Reports Positive Ph 2 Osavampator Data In MDD

    22 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-positive-new-data-from-phase-2-study-of-osavampator-in-adults-with-major-depressive-disorder-302562476.html

    PR NEWSWIRE
    22 Sep 2025
    Share Share
    Neurocrine Biosciences to Unveil Osavampator Phase 2 Data
    Neurocrine Biosciences to Unveil Osavampator Phase 2 Data

    17 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-data-from-phase-2-study-of-osavampator-in-adults-with-major-depressive-disorder-at-38th-annual-psych-congress-2025-302558274.html

    PR NEWSWIRE
    17 Sep 2025
    Share Share